Clinical Trials Logo

Clinical Trial Summary

A phase III, multicenter, randomized, open-label, french study comparing: - Arm A : Radiotherapy alone (66 to 70 Gy; 5 fractions/week; 1fraction/day; 2 Gy/fraction) (IMRT or protontherapy) - Arm B: Radiotherapy (66 to 70 Gy; 5 fractions/week; 1fraction/day; 2 Gy/fraction; IMRT or protontherapy) + concomitant cisplatin 100 mg/m2 IV on day 1 - J22 - 43 (3 cycles)

Clinical Trial Description

Carcinomas of the sinuses and the salivary glands are rare. They are heterogeneous in terms of anatomical sites and histology subtypes. For this reason and in the absence of prospective study, their treatment is still largely extrapolated from data of frequent carcinomas of the upper digestive tract. These tumors are most often diagnosed lately. Their treatment is based on a multimodal management of care, with a central place for the surgery and radiotherapy (Proof level Grade C). Despite the advances in surgical techniques, and the addition of radiation therapy, the 5-year overall survival probability does not exceed 65% mainly due to a loco regional development. In this context, a chemotherapy administered concomitantly to radiotherapy, could increase the efficacy of the locoregional treatment by a radiosensibilization process and regardless of the histology. This point is regularly discussed in multidisciplinary concertation meeting, including bi-monthly national REFCOR meeting (network of French Expertise on rare Cancers of the head and neck). At present, the lack of data brings even to discuss the addition of cisplatin to exclusive irradiation of unresectable or not operable tumors. No randomized study has been published in this context. The first comparative prospective study addressing the addition of weekly cisplatin to the adjuvant irradiation of salivary, is a phase II randomized study (Radiation Therapy Oncology Group - RTOG 1008) currently enrolling patients in the United States of America. The Sponsor propose to conduct a phase III randomized study evaluating the impact of the addition of cisplatin to a treatment by radiotherapy in adjuvant setting (≥ 65 Gy) in case of a high risk of recurrence: case of radioresistant histologies (e.g. cystic fibrosis adenoids carcinomas), or case of unfavourable histo-prognostic criteria (incomplete resection, presence of emboli, etc.) in this population. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT02998385
Study type Interventional
Source Groupe Oncologie Radiotherapie Tete et Cou
Contact François Régis FERRAND, MD
Phone +33 1 43 98 50 78
Email [email protected]
Status Recruiting
Phase Phase 3
Start date January 20, 2017
Completion date November 2026

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02999087 - Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH) Phase 3
Recruiting NCT03292250 - Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)] Phase 2
Recruiting NCT04606940 - Study of Circulating Tumor DNA (ctDNA) Kinetics in Immuno-oncology (IO-KIN)
Recruiting NCT03356587 - A Biomarker-driven, Open Label, Single Arm, Multicentre Phase II Study of Abemaciclib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Who Failed to Platinum-based Therapy Phase 2
Recruiting NCT03719690 - Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy Phase 2
Active, not recruiting NCT03367780 - Dose-Effect Relation of Salivary Gland Irradiation
Enrolling by invitation NCT04141449 - A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation Phase 2
Recruiting NCT04042935 - Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC Phase 1
Recruiting NCT04157985 - Evaluation of the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors Phase 3
Recruiting NCT04279509 - Selecting Chemotherapy With High-throughput Drug Screen Assay Using Patient Derived Organoids in Patients With Refractory Solid Tumours (SCORE) N/A
Recruiting NCT04272333 - Intratumoral Microdosing of Motolimod in HNSCC Early Phase 1
Recruiting NCT03652142 - Predictive Biomarkers for Response to Nivolumab in Head and Neck Squamous Cell Carcinoma
Recruiting NCT03082534 - Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Phase 2
Active, not recruiting NCT03107182 - Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer Phase 2
Recruiting NCT04169074 - Modulation of the Tumor Microenvironment by Abemaciclib in Operable HPV-Negative Head and Neck Cancer (HNC) Phase 2
Not yet recruiting NCT04861467 - Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Phase 2
Not yet recruiting NCT04811027 - Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC Phase 2
Recruiting NCT03726775 - Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN Phase 2
Completed NCT03740100 - Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations Phase 2
Recruiting NCT04722523 - A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer Phase 1